Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00799331 | Exploratory Study to Assess the Pharmacokinetics of AZD5985 | PHASE1 | COMPLETED | 32 | — | — | Nov 1, 2008 | Feb 1, 2009 | Jun 9, 2009 | 1 | Germany |
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | AZD5985 |
| B | EXPERIMENTAL | placebo |
| Name | Type | Description |
|---|---|---|
| AZD5985 | DRUG | Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits. |
| placebo | DRUG | Oral suspension. |
Inclusion Criteria: * Provision of signed, written and dated informed consent prior to any study specific procedures. * Healthy male subjects aged 18 to 45 years (inclusive). * Have a body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg. * Be non-smoker or ...